The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial

Efficacy and safety of AXS‐05, a novel, oral, NMDA‐receptor antagonist with multimodal activity, in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1, a phase 2/3, double‐blind, active and placebo‐controlled trial

Alzheimer s & Dementia ◽

10.1002/alz.047684 ◽

2020 ◽

Vol 16 (S9) ◽

Author(s):

Cedric O'Gorman ◽

Amanda Jones ◽

Jeffrey L. Cummings ◽

Herriot Tabuteau

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Nmda Receptor ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 2 ◽

Efficacy And Safety ◽

Efficacy and safety of AXS‐05, a novel oral NMDA receptor antagonist with multimodal activity in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1 — A phase 2/3, double‐blind, active and placebo‐controlled trial

Alzheimer s & Dementia ◽

10.1002/alz.048299 ◽

2020 ◽

Vol 16 (S6) ◽

Author(s):

Cedric O'Gorman ◽

Amanda Jones ◽

Jeffrey L. Cummings ◽

Herriot Tabuteau

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Nmda Receptor ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 2 ◽

Efficacy And Safety ◽

The efficacy of the NMDA receptor antagonist amantadine in the treatment of neuropathic cancer pain: A double blind, randomized, placebo-controlled trial

European Journal of Cancer ◽

10.1016/s0959-8049(97)84616-3 ◽

1997 ◽

Vol 33 ◽

pp. S53

Author(s):

D. Pud ◽

E. Eisenberg ◽

A. Spitzer

Keyword(s):

Nmda Receptor ◽

Cancer Pain ◽

Receptor Antagonist ◽

Controlled Trial ◽

Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial

CNS Drugs ◽

10.1007/s40263-018-0506-8 ◽

2018 ◽

Vol 32 (2) ◽

pp. 179-187 ◽

Cited By ~ 4

Author(s):

Jayashri Kulkarni ◽

Natalie Thomas ◽

Abdul-Rahman Hudaib ◽

Emorfia Gavrilidis ◽

Jasmin Grigg ◽

...

Keyword(s):

Borderline Personality Disorder ◽

Nmda Receptor ◽

Personality Disorder ◽

Receptor Antagonist ◽

Controlled Trial ◽

Borderline Personality ◽

Adjunctive Treatment ◽

Double Blind ◽

Double Blind Placebo

Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-d-aspartate (NMDA) receptor antagonist ketamine – a double-blind, cross-over comparison with alfentanil and placebo

Pain ◽

10.1016/s0304-3959(02)00122-7 ◽

2003 ◽

Vol 101 (3) ◽

pp. 229-235 ◽

Cited By ~ 123

Author(s):

E Jørum ◽

T Warncke ◽

A Stubhaug

Keyword(s):

Neuropathic Pain ◽

Nmda Receptor ◽

Receptor Antagonist ◽

Double Blind ◽

Cold Allodynia

Neurophysiological and Clinical Effects of the NMDA Receptor Antagonist Lanicemine (BHV-5500) in PTSD: A Randomized, Double-Blind, Placebo-Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3809804 ◽

2021 ◽

Author(s):

Nithya Ramakrishnan ◽

Marijn Lijffijt ◽

Charles E. Green ◽

Nicholas L. Balderston ◽

Nicholas Murphy ◽

...

Keyword(s):

Nmda Receptor ◽

Receptor Antagonist ◽

Controlled Trial ◽

Clinical Effects ◽

Double Blind ◽

Double Blind Placebo

Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV‐5500) in PTSD: A randomized, double‐blind, placebo‐controlled trial

Depression and Anxiety ◽

10.1002/da.23194 ◽

2021 ◽

Author(s):

Nithya Ramakrishnan ◽

Marijn Lijffijt ◽

Charles E. Green ◽

Nicholas L. Balderston ◽

Nicholas Murphy ◽

...

Keyword(s):

Nmda Receptor ◽

Receptor Antagonist ◽

Controlled Trial ◽

Clinical Effects ◽

Double Blind ◽

Double Blind Placebo

Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature

Expert Opinion on Drug Metabolism & Toxicology ◽

10.1080/17425255.2019.1689958 ◽

2019 ◽

Vol 15 (12) ◽

pp. 1033-1041 ◽

Cited By ~ 6

Author(s):

Jasper Kamp ◽

Monique Van Velzen ◽

Erik Olofsen ◽

Martijn Boon ◽

Albert Dahan ◽

...

Keyword(s):

Neuropathic Pain ◽

Nmda Receptor ◽

Receptor Antagonist ◽

Recent Literature ◽

Chronic Neuropathic Pain

Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine?

Pain ◽

10.1016/s0304-3959(97)00198-x ◽

1998 ◽

Vol 74 (2) ◽

pp. 337-339 ◽

Cited By ~ 41

Author(s):

Elon Eisenberg ◽

Dorit Pud

Keyword(s):

Neuropathic Pain ◽

Nmda Receptor ◽

Receptor Antagonist ◽

Acute Administration ◽

Chronic Neuropathic Pain

A randomised double-blind controlled trial of s-ketamine versus placebo in conjunction with best pain management in neuropathic pain in cancer patients

http://isrctn.org/> ◽

10.1186/isrctn49116945 ◽

2012 ◽

Author(s):

Marie Fallon

Keyword(s):

Neuropathic Pain ◽

Pain Management ◽

Cancer Patients ◽

Controlled Trial ◽